Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer

The Quick Take
The study evaluates patients with liver cancer at high risk of recurrence following surgical resection Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, Oct. 21, 2026 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company...
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire.


